Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Ramon Bataller, MD, PhD


Chief of Hepatology


Phone: 412-383-4241

Office: 200 Lothrop Street
BST W1144
Pittsburgh, PA 15213
Phone: 412-383-4241
Fax: 412-648-4055
Administrative Assistant:
Nikole Jones
Address: 200 Lothrop Street
BST W1146A
Pittsburgh, PA 15213
Phone: 412-383-4413
Fax: 412-648-4055
Education and Training
MD, University of Valencia - Valencia, Spain, 1994
Research Fellow (PhD), Liver Unit, Hospital Clinic - Barcelona, Spain, 2000
Resident & Board Certification/Gastroenterology, Hospital Clinic - Barcelona, Spain, 1994
Research Interest
As the Chief of Hepatology, Dr. Bataller's research interests include liver fibrosis and the mechanisms and determinants of mortality of alcoholic liver disease. He has performed translational studies including human samples and experimental models of liver disease primarily. A more recent research interest of Dr. Battaler involves his exploration of the global public health aspects of alcoholic liver disease. He is the PI for an NIH-funded consortium (InTeam) for translational research of alcoholic hepatitis. InTeam main goals include the identification of molecular subtypes and the identification of novel targets for therapy.
Clinical Interest
Dr. Bataller's clinical interests include the management of patients with alcoholic and non-alcoholic fatty liver disease and critically-ill cirrhotic patients.
Educational Interest
Dr. Bataller is committed to advanced education in hepatology related to the Division of Gastroenterology, Hepatology and Nutrition's accredited gastroenterology and advanced hepatology fellowships.
Selected Publications:
Ouyang, X., Han, S., Zhang, J., Nemeth, B. T., Pacher, P., Feng, D., Bataller, R., Cabezas, J., Starkel, P., Caballeria, J., Pongratz, R. L., Caii, S., Schnabl, B., Hogue, R., Chen, Y., Yang, W., Garcia Martinez, I., Wang, F., Gao, B., Torok, N. J. Digoxin Suppresses Pyruvate Kinase M2 Promoted HIF-1a Transactivation in Steatohepatitis. Cell Metabolism. 2018; 27: 339-50.
Altamirano, J., Lopez-Pelayo, H., Michelena, J., Jones, P. D., Ortega, L., Gines, P., Caballeria, J., Gual, A., Bataller, R., Lligona, A. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis prediction and impact on long-term survival. Hepatology. 2017; 66: 1842-53.
Ndugga N, Lightbourne TG, Javaherian K, Cabezas J, Verma N, Barriett AS 4th, Bataller R. Disparities between research attention and burden in liver diseases: Implications on uneven advances in pharmacological therapies in Europe and the USA. BMJ Open. 2017; 7(3): e013620.
Cheong J, Galanko JA, Arora S, Cabezas J, Ndugga NJ, Lucey MR, Hayashi PH, Barritt AS, Bataller R. Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation. Liver International. 2017; 37(2): 290-8.
Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, MonceraK, Beeri K, Chen CS, Freese K..., Bataller R, Starkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. Journal of Clinical Investigation. 2017; 127(7): 2829-41.
Odena G, Chen J, Lozano JJ, Altamirano J, Rodrigo-Torres D, Affo S, Morales-Ibanez O, Matsushita H, Zou J, Dumitru R, Caballeria J, Gines P, Arroyo V, You M, Rautou PE, Valla D, Cres F,, Seki E, Sancho-Bru P, Bataller R. LPS-TLR4 pathway mediates ductular cell expansion in alcoholic hepatitis. Scientific Reports. 2016; 6: 35610.
Stickel F, Datz C, Hampe J, Bataller R. Pathophysiology and management of alcoholic liver disease: Update 2016. Gut Liver. 2016; 11(2): 173-88.
Farooq MO, Bataller R. Pathogenesis and management of alcoholic liver disease. Digest Diseases and Sciences. 2016; 34(4): 347-55.
Shah N, Bataller R. Cell-based therapy to reverse advanced alcoholic liver fibrosis. Annuals of Hepatology. 2016; 5(5): 806-8.
Sponsored Research/Activities
Title: Liver-Enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis
Role: Principal Investigator
Funding Agency: National Institute on Alcohol Abuse & Alcoholism
Grant Number: R01 AA026972
Start Year: 2018
End Year: 2023
Title: Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies (Collaborative U01)
Role: Principal Investigator
Funding Agency: National Institute on Alcohol Abuse & Alcoholism
Grant Number: U01 AA026978
Start Year: 2018
End Year: 2022
Title: Molecular Subtypes for Targeted Therapies in Alcoholic Hepatitis
Role: Principal Investigator
Funding Agency: National Institute on Alcohol Abuse & Alcoholism
Grant Number: U01 AA021908
Start Year: 2017
End Year: 2019
Notable Achievements
Permanent member, Hepatobiliary Pathophysiology Study Section NIH, 2018
Member of the American College of Gastroenterology, 2016
Member of the Latinoamerican Association for the Study of the Liver (ALEH), 2016
AASLD Education Committee Member, 2016
Honoary Member of the faculty of Medicine, University of Antiquia, Colombia, 2015
Best Poster Presentation, 46th Annual Meeting of the European association for the Study of the Liver, 2011
Research Recognition Award from the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, 2010
Posdoctoral Research Fellowship Award from the American Liver Foundation - Chapel Hill, NC, 2003